CAMBRIDGE, England–(BUSINESS WIRE)–Congenica, a digital health company that enables precision medicine through its world-leading diagnostic decision support platform for genomic data, today announces the appointment of Robert Denison as Chief Executive Officer (CEO). He will also join the Board of the company. Rob has a strong history of growing businesses ranging from start-ups through to … [Read more…]
Prurigo nodularis is a rare, potentially debilitating, inflammatory skin disease characterized by disfiguring skin nodules often covering extensive areas of the body, and an intense and chronic itch There are currently no approved therapeutic options Nemolizumab is a first-in-class investigational monoclonal antibody that blocks the signaling of IL-31, a key neuroimmune cytokine involved in the … [Read more…]
Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan demonstrated superior progression-free and overall survival versus chemotherapy TOKYO & MUNICH–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as monotherapy for the treatment of adult patients with … [Read more…]
Shareholders approved all proposed resolutions LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The … [Read more…]
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in clinical trial of the Company’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 in China. ICP-189 is a potent and selective oral … [Read more…]
The three-year, $750,000 commitment is expected to improve overall health and save lives SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) — QuidelOrtho announces that its subsidiary, Quidel Corporation, is collaborating with the American Heart Association, the leading voluntary health organization devoted to a world of longer and healthier lives, to improve the health of San … [Read more…]
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross … [Read more…]
TORONTO–(BUSINESS WIRE)–Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the “Meeting”). Each of the matters voted upon at the Meeting as set out below … [Read more…]
– Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products – Precision to Develop a Single ARCUS® Nuclease Designed for Safe and Efficient In Vivo Gene Insertion – Collaboration Combines Precision’s Proprietary ARCUS Genome … [Read more…]
WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, announced today that it has filed suit in United States District Court for the District of Massachusetts against Pfizer, Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the ’953 … [Read more…]
